<DOC>
	<DOCNO>NCT01830231</DOCNO>
	<brief_summary>Due limit experience cabazitaxel TCCU , study start randomised phase II study . The aim phase II study evaluate response rate ( CR + PR ) sufficiently high study treatment regimens phase III setting .</brief_summary>
	<brief_title>Cabazitaxel vs. Vinflunine Metastatic Locally Advanced Transitional Cell Carcinoma Urothelium ( TCCU )</brief_title>
	<detailed_description>Once confirm subject fulfil eligibility criterion sign informed consent , randomise receive treatment base cabazitaxel vinflunine accord follow study schema : ( Randomize 1:1 ) - Cabazitaxel 25 mg/m2 q3w - Vinflunine 250-320 mg/m2 q3w Random assignment treatment stratify presence 0 versus 1 follow unfavourable prognostic risk factor propose recently Bellmunt et al . ( 1 ) : - Eastern Cooperative Oncology Group ( ECOG ) PS 1 . - Anaemia Hb &lt; 10 g/dL . - Presence liver metastasis . All patient enrol study receive cycle treatment study medication ( cabazitaxel vinflunine ) every 21 day disease progression intolerable/unacceptable toxicity . Tumour evaluation schedule every 6 week progression</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Written inform consent Histologically confirm TCCU ( urinary bladder , urethra , ureter renal pelvis ) . Patients mixed histology may enrol TCCU predominant component ( i.e. , &gt; 50 % histopathology sample ) exception neuroendocrine small cell carcinoma . Advanced disease define locally advanced tumour consider unresectable ( T4b ) , node involvement inguinal area aortic bifurcation ( consider distant node metastasis ) metastasis distant organ . Patient receive one prior platinumbased chemotherapy treatment locally advanced stage IV TCCU . Prior platinumbased adjuvant neoadjuvant therapy allow 6 month elapse since end adjuvant neoadjuvant therapy till tumour relapse . At least one measurable tumour lesion ( measurable disease , define Response Evaluation Criteria Solid Tumors ( RECIST ) criteria v1.1 â‰¥18 year . ECOG PS 0 1 . May ONE follow unfavourable risk factor : 1. haemoglobin &lt; 10 g/dL 2. presence liver metastasis 3 . ECOG PS 1 Life expectancy least 12 week . Adequate hematologic , hepatic , renal function , define : Females childbearing potential must negative serum pregnancy test within 7 day study entry . Patients 2 follow unfavourable risk factor : 1 . Haemoglobin &lt; 10 g/L 2 . Liver metastasis 3 . ECOG PS 1 . Women currently pregnant breastfeed . Any unresolved nonhematologic Adverse Event ( AE ) grade &gt; 1 ( Common Toxicity Criteria Adverse Effects ( NCICTCAE ) Version 4.0 ) previous anticancer therapy ( alopecia ) Patients undergone major surgery , radiation therapy treatment chemotherapy investigational agent within 28 day prior Study day 1 . Evidence severe uncontrolled systemic disease concurrent condition History another neoplasm . History hypersensitivity reaction taxanes ( docetaxel ) ( cabazitaxel specific criterion ) , vinca alkaloid ( vinflunine specific criterion ) formulation excipients , include polysorbate 80 clear evidence symptom central nervous system metastasis ( cabazitaxel specific criterion ) . Clinically significant cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>TCCU</keyword>
	<keyword>Vinflunine</keyword>
	<keyword>Cabazitaxel</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Locally advance</keyword>
</DOC>